Reducing Gadolinium Exposure in Patients Undergoing Monitoring for Meningiomas

Background Due to the non-malignant and slow-growing nature of many meningiomas, surveillance with serial magnetic resonance imaging (MRI) serves as an acceptable management plan. However, repeated imaging with gold-standard contrast-based studies may lead to contrast-associated adverse effects. Non-gadolinium T2 sequences may serve as a suitable alternative without the risk of adverse effects of contrast. Thus, this study sought to investigate the agreement between post-contrast T1 and non-gadolinium T2 MRI sequences in the measurement of meningioma growth. Methodology The Virginia Commonwealth University School of Medicine (VCU SOM) brain tumor database was used to create a cohort of meningioma patients and determine the number of patients who had T1 post-contrast imaging accompanied by readily measurable imaging from either T2 fast spin echo (FSE) or T2 fluid-attenuated inversion recovery (FLAIR) sequences. Measurements of the largest axial and perpendicular diameters of each tumor were conducted by two independent observers using T1 post-contrast, T2 FSE, and T2 FLAIR imaging series. Lin’s concordance correlation coefficient (CCC) was calculated to assess inter-rater reliability between observers and agreement between measurements of tumor diameter among the different imaging sequences. Results In total, 33 patients (average age = 72.1 ± 12.9 years, 90% female) with meningiomas were extracted from our database, with 22 (66.7%) undergoing T1 post-contrast imaging accompanied with readily measurable imaging from T2 FSE and/or T2 FLAIR sequences. The inter-rater reliability between the measurements of T1 axial and perpendicular diameters was 0.96 (95% confidence interval (CI) = 0.92-0.98) and 0.92 (95% CI = 0.83-0.97), respectively. The inter-rater reliability between the measurements of T2 axial perpendicular diameters was 0.93 (95% = CI 0.92-0.97) and 0.89 (95% CI = 0.74-0.95), respectively. The agreements between the measurement of T1 and T2 FSE axial diameter by each observer were 0.97 (95% CI = 0.93-0.98) and 0.92 (95% CI = 0.81-0.97). The agreements between the measurements of T1 and T2 FSE perpendicular diameter measurements by each observer were 0.98 (95% CI = 0.95-0.99) and 0.88 (95% CI = 0.73-0.95). Conclusions Two-thirds of our patients had meningiomas that were readily measurable on either T2 FSE or T2 FLAIR sequences. Additionally, there was excellent inter-rater reliability between the observers in our study as well as an agreement between individual measurements of T1 post-contrast and T2 FSE tumor diameters. These findings suggest that T2 FSE may serve as a safe and similarly effective surveillance method for the long-term management of meningioma patients.

[1]  Sohil H. Patel,et al.  Intracranial meningioma surveillance using volumetrics from T2‐weighted MRI , 2021, Journal of neuroimaging : official journal of the American Society of Neuroimaging.

[2]  M. Vargas,et al.  Is Contrast Medium Really Needed for Follow-up MRI of Untreated Intracranial Meningiomas? , 2021, American Journal of Neuroradiology.

[3]  M. Hayden Gephart,et al.  Non-Contrast T2-Weighted MR Sequences for Long Term Monitoring of Asymptomatic Convexity Meningiomas. , 2019, World neurosurgery.

[4]  K. Workman,et al.  Comparison of ABC/2 estimation and a volumetric computerized method for measurement of meningiomas using magnetic resonance imaging , 2019, Journal of Neuro-Oncology.

[5]  A. Bücker,et al.  Gadoliniumablagerungen – Morbus Gadolinium , 2019, Der Radiologe.

[6]  A. Agildere,et al.  Can unenhanced brain magnetic resonance imaging be used in routine follow up of meningiomas to avoid gadolinium deposition in brain? , 2019, Clinical imaging.

[7]  W. Moon,et al.  Gadolinium Deposition in the Brain: Current Updates , 2018, Korean journal of radiology.

[8]  C. James,et al.  An overview of meningiomas. , 2018, Future oncology.

[9]  Rosewinter Kodzwa Updates to the ACR Manual on Contrast Media. , 2017, Radiologic technology.

[10]  Fernando Calamante,et al.  Gadolinium deposition in the brain: summary of evidence and recommendations , 2017, The Lancet Neurology.

[11]  Matthew G. Crowson,et al.  Cost-effectiveness analysis of a non-contrast screening MRI protocol for vestibular schwannoma in patients with asymmetric sensorineural hearing loss , 2017, Neuroradiology.

[12]  M. Weller,et al.  EANO guidelines for the diagnosis and treatment of meningiomas. , 2016, The Lancet. Oncology.

[13]  Erich P Huang,et al.  RECIST 1.1-Update and clarification: From the RECIST committee. , 2016, European journal of cancer.

[14]  Terry K Koo,et al.  A Guideline of Selecting and Reporting Intraclass Correlation Coefficients for Reliability Research. , 2016, Journal Chiropractic Medicine.

[15]  Daisuke Takenaka,et al.  High signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted MR images: relationship with increasing cumulative dose of a gadolinium-based contrast material. , 2014, Radiology.

[16]  P. Brotchie,et al.  Magnetic resonance imaging of meningiomas: a pictorial review , 2014, Insights into Imaging.

[17]  C. Juan,et al.  Calculating the tumor volume of acoustic neuromas: Comparison of ABC/2 formula with planimetry method , 2013, Clinical Neurology and Neurosurgery.

[18]  D. Saloner,et al.  Modern meningioma imaging techniques , 2010, Journal of Neuro-Oncology.

[19]  A. D. Van den Abbeele,et al.  Revised RECIST guideline version 1.1: What oncologists want to know and what radiologists need to know. , 2010, AJR. American journal of roentgenology.

[20]  Henrik S. Thomsen,et al.  Nephrogenic systemic fibrosis (NSF): a late adverse reaction to some of the gadolinium based contrast agents , 2007, Cancer imaging : the official publication of the International Cancer Imaging Society.

[21]  H. Thomsen Nephrogenic systemic fibrosis: a serious late adverse reaction to gadodiamide , 2006, European Radiology.

[22]  Lone Skov,et al.  Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. , 2006, Journal of the American Society of Nephrology : JASN.

[23]  L. Lin,et al.  A concordance correlation coefficient to evaluate reproducibility. , 1989, Biometrics.

[24]  D. Altman,et al.  STATISTICAL METHODS FOR ASSESSING AGREEMENT BETWEEN TWO METHODS OF CLINICAL MEASUREMENT , 1986, The Lancet.

[25]  J. Barnholtz-Sloan,et al.  CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012-2016. , 2019, Neuro-oncology.